Skip to content

Next Generation Sequencing Analysis of Patients with Spontaneous Dissection of Cervical Arteries

Next Generation Sequencing (NGS) Analysis of Patients with Spontaneous Dissection of Cervical Arteries (sCeAD), a Multi-centric, Interventional, Cohort Study

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06862063
Acronym
NASCeAD
Enrollment
145
Registered
2025-03-06
Start date
2024-12-01
Completion date
2030-12-01
Last updated
2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dissecting Aneurysm, Dissection Arterial, Dissection Carotid Artery

Brief summary

The goal of this observational study is to analyze the existence of a genetic predisposition in patients with spontaneous dissections of the cervical arteries (SCeAD). The main questions it aims to answer are: 1. Which is the prevalence of pathogenic variants in genes coding for proteins involved in the structure or function of the connective tissue in adult patients with spontaneous dissections of the cervical arteries? 2. Which are the clinical characteristics of each single genetic variant identified? 3. Which are the clinical, radiological, laboratory variables associated with the finding of a pathogenic variant? 4. Are there differences between patients with SCeAD who have a pathogenic variant in a gene coding for proteins involved in the structure or function of the connective tissue and those who not? 5. There are differences in the risk of SCeAD recurrence between patients with SCeAD who have a pathogenic variant in a gene coding for proteins involved in the structure or function of the connective tissue and those who not? 6. There are differences in the risk of SCeAD recurrence based on the specific typology of genetic variant found? Participants will be asked to undergo: * a whole-CT total-body with contrast; * a dysmorphological visit; * a blood sampling for genetic testing; * a neurological visit; * Some follow-up visits.

Interventions

DIAGNOSTIC_TESTGenetic testing

Each eligible patient will undergo a blood sample to perform a genetic analysis through Next Generation Sequencing (NGS) technique in order to analyze a high number of genes involved in the structure/function of connective tissue

Sponsors

Fondazione Mondino
CollaboratorOTHER
University of Rome Tor Vergata
CollaboratorOTHER
Azienda Policlinico Umberto I
CollaboratorOTHER
San Camillo Hospital, Rome
CollaboratorOTHER
I.R.C.C.S. Fondazione Santa Lucia
CollaboratorOTHER
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
CollaboratorOTHER
Ospedale Policlinico San Martino
CollaboratorOTHER
Istituto Neurologico Mediterraneo Neuromed S. R. L
CollaboratorOTHER
IRCCS Istituto delle Scienze Neurologiche di Bologna
CollaboratorOTHER
Ospedale Guzzardi di Vittoria
CollaboratorUNKNOWN
Santo Spirito Hospital, Italy
CollaboratorOTHER
Azienda Ospedaliera di Rilievo Nazionale A.Cardarelli
CollaboratorOTHER
Istituto Clinico Humanitas
CollaboratorOTHER
Ospedale V. Fazzi
CollaboratorOTHER
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult age (≥18 years); * Presence of a dissection of one or more cervical arteries (carotid or vertebrobasilar district), defined as the finding, on an appropriate radiological examination (CT and/or MRI of the neck and brain district with/without contrast medium and/or digital subtraction angiography and/or echocolordoppler of the epiaortic vessels) of intramural hematoma, pseudoaneurysmal dilation, intimal flap, double lumen, long tapering stenosis or occlusion ≥2 cm above the carotid bifurcation with finding of an aneurysmal dilation or a long tapering stenosis after recanalization of the vessel; * At least one or more of the following criteria: * Radiological evidence on CT and/or MRI with/without contrast and/or digital subtraction angiography and/or color Doppler ultrasound of vessel wall anomalies (such as aneurysms, dissections, tortuosity, ectasia or vascular stenosis) in one or more vascular districts in addition to that of the known dissection; * Family history of: * vessel dissections and/or sudden death and/or cerebrovascular or cardiovascular diseases at a young age; * spontaneous perforation of internal organs and/or dehiscence and/or laxity of connective tissue (spontaneous prolapses); * dysmorphological abnormalities at the clinical examination (including Beighton score ≥5 or Marfan score ≥7), laboratory and/or radiological findings suggestive of connective tissue disease or other genetic condition known to be associated with the development of aneurysms or alterations of the vessel wall; * Written informed consent

Exclusion criteria

* Recent history of trauma clearly related in type, location and dynamics to the development of dissection; * Iatrogenic dissection following endovascular procedure; * Exclusively intracranial dissection; * Fibromuscular dysplasia.

Design outcomes

Primary

MeasureTime frameDescription
Definition of the percentage prevalence (n - %) of pathogenic variants in patients with Spontaneous Cervical Artery Dissection (SCeAD)Through study completion, an average of 2 years and six monthsTo define the percentage prevalence (n - %) of pathogenic variants of genes encoding proteins involved in the structure/function of connective tissue in patients with spontaneous dissection of the cervical arteries

Secondary

MeasureTime frameDescription
Evaluation of the percentage prevalence (n - %) of each pathogenic variant in genes encoding connective tissue proteins in patients with spontaneous dissection of the cervical arteriesThrough study completion, an average of 2 years and six monthsDescription of the typology and percentage prevalence (n - %) of individual pathogenic variants of genes encoding proteins involved in the structure/function of connective tissue in patients with spontaneous dissections of the Cervical arteries
Identification of clinical predictors of pathogenic variants in genes encoding connective tissue proteins in patients with spontaneous cervical artery dissectionThrough study completion, an average of 2 years and six monthsPercentage prevalence (n - %) of clinical predictors of pathogenic variants in genes encoding proteins involved in the structure/function of connective tissue in patients with spontaneous dissection of the cervical arteries through multivariable regression models. In particular, clinical (eg. Beighton score, Marfan score, symptoms that lead to the finding of the dissection, etc), radiological (eg. the presence of vascular abnormalities in other vascular districts, the aspect of the cervical artery dissection at the US, CT, or MRI examination, etc.), and laboratory parameters (eg. hyperhomocisteinemia, immunological screening, CRP, etc.) will be compared between patients with spontaneous dissections of the cervical arteries who have a pthogenic variant of genes encoding for connective tissue proteins and those who not.
Assessment of the risk of artery dissection recurrence in patients with spontaneous cervical artery dissection carrying a pathogenic variant in those without through the ODD ratioThrough study completion, an average of 2 years and six monthsComparison of the risk of recurrence of vascular dissections in the cervical arteries or in other vascular districts in patients with spontaneous cervical artery dissection carrying a pathogenic variant in genes encoding proteins involved in connective tissue structure/function and in those without it by calculating the ODD ratio
Definition of the prevalence of pathogenic variants in other genesThrough study completion, an average of 2 years and six monthsPercentage prevalence (n - %) of individual pathogenic variants of genes encoding proteins not involved in the structure/function of connective tissue in patients with spontaneous dissection of the cervical arteries and correlation of the same with individual clinical phenotypes;

Countries

Italy

Contacts

Primary ContactGiovanni Frisullo, MD, PhD
giovanni.frisullo@policlinicogemmelli.it+390630156321
Backup ContactIrene Scala, MD
irene.scala@guest.policlinicogemelli.it+390630156321

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026